1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one Chemical Properties

Density 

1.272±0.06 g/cm3(Predicted)

storage temp. 

room temp

solubility 

DMSO:100.0(Max Conc. mg/mL);350.4(Max Conc. mM)
H2O:5.0(Max Conc. mg/mL);17.5(Max Conc. mM)

form 

powder

pka

13.03±0.50(Predicted)

color 

white to beige

InChI

InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1

InChIKey

CBRJPFGIXUFMTM-WDEREUQCSA-N

SMILES

C(N1C[C@H](NC2N=CN=C3NC=CC3=2)CC[C@@H]1C)(=O)C=C

1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one Usage And Synthesis

Biochem/physiol Actions

PF-06651600 is a potent and selective JAK3 inhibitor.

1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one(1792180-81-4)Related Product Information

• PF-06700841 tosylate
• PF-06650833
• PF-06447475
• Lorlatinib (PF-06463922)
• 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide
• 2-[[(2E)-3-(2-NAPHTHALENYL)-1-OXO-2-BUTEN-1-YL]AMINO]BENZOIC ACID
• Upadacitinib
• Q-VD-OPh hydrate
• N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide
• H3B-6527
• Senexin B
• 2-(2-((4-bromophenyl)amino)-2-oxoethoxy)-N-(2-(methyl(phenyl)amino)-2-oxoethyl)benzamide
• (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide
• BMS-986205
• Budiodarone tartrate
• COH-29